Scioderm Obtains $20,000,000 Series B Funding Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    1007 Slater Road Durham, NC 27703 USA
  • Company Description
    The core business focus of Scioderm is the development of innovative dermatological drugs. Our strategy is to in-license or acquire early to mid-stage pharmaceutical products with the intent to develop the topical products.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    The proceeds will be used to fund the development of ZorblisaTM (SD-101), a proprietary topical therapy being developed for the treatment of all patients with Epidermolysis Bullosa (EB), through completion of the US and EU clinical registration programs.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy